Biogen Signs an Exclusive Commercialization Agreement with Samsung Bioepis to Expand its Biosimilars Portfolio
Shots: Samsung Bioepis to receive $100M up front, up to $210M development, regulatory and commercial milestones and will be responsible for the development
[Read More...]